*The above diagram is just an illustration of the product.
Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product
labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.
MAGICTOUCH ED
Quick Facts
Erectile Dysfunction (ED) is defined as the recurrent inability to achieve and maintain an erection satisfactory for sexual intercourse.
• ED is an important and growing health problem. It is estimated that more than 200 million men (between 40 – 70 year) suffer from ED.
• Male sexual arousal is a complex process that involves the brain, hormones, emotions, nerves, muscles and blood vessels. Erectile Dysfunction can result from a problem with any of these. In many cases, Erectile Dysfunction is caused by something physical.
• In many cases, Erectile Dysfunction is caused by blockage in arteries supplying blood to penis (external genitalia), which is commonly called as “vasculogenic ED”.
• Common causes include Heart disease, Clogged blood vessels (atherosclerosis – in more than 40% of cases), High cholesterol, High blood pressure, Diabetes (in more than 30% of cases), Obesity, Tobacco use.
• Arterial Inflow atherosclerotic disease (usually pudendal and Dorsal penis arteries stenosis) is a common etiology. Patients who do not respond anymore to PDEI- 5 inhibitors therapy (1° line therapy), may be treated by percutaneous transluminal angioplasty.
• Magic Touch – ED is a Sirolimus Coated Balloon for treatment of ED for male patients with de novo and restenotic lesions in the internal pudendal, dorsal or urethral arteries
CONFIDENCE WITH EVIDENCE
Treatment Success Reflected by Minimum Clinically Relevant Improvement in the International Index of Erectile Function-5 (IIEF-5) score with Magic Touch – ED.
NANOLUTE TECHNOLOGY
PHARMACOKINETIC STUDY
In ISR Lesion*
SIROLIMUS DISTRIBUTION STUDY
DTF labelled Sirolimus was used to assess the drug distribution following DCB treatment*
A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L: Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56